← Back to Nuqta Atlas
Editorially curated · ae-egp-pharmacogenomics
Emirati Genome Program Pharmacogenomics Integration
EGP-derived pharmacogenomic reports are integrated into the health-information exchange to help clinicians select and dose medicines according to inherited variation.
01 / Project overview
What the record establishes.
- Geographic scope
- Abu Dhabi clinical network with national EGP participants
- Project type
- clinical pharmacogenomics implementation
- Research domain
- pharmacogenomics and precision prescribing
- Years
- 2023–
- Lifecycle status
- operational
- Status basis
- DoH announced clinician access to participant pharmacogenomic reports through Malaffi in September 2024 following the 2023 implementation agreement.
- Status evidence date
- 2024-09-01
- Scale
- Population scale not separately reported; available to consented EGP participants with generated reports.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Department of Health - Abu Dhabi · M42
- Partner organizations
- Malaffi health information exchange · Abu Dhabi healthcare providers
- Organism / population
- Consenting Emirati Genome Program participants
03 / Data and access
What exists and how it can be reached.
Data types
- pharmacogenomic variants
- clinical decision support
- electronic health records
Data access
Authorized clinicians through Malaffi; patients participate through EGP consent.
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Named national translational genomics deployment embedded in routine clinical infrastructure.
Editorial note
Direct downstream use of EGP data, not a new cohort.
Sources
- primary record source Verified 2026-08-15
- additional record source Verified 2026-08-15
Release v0.2.0